Compare State Street SPDR S&P Biotech ETF (XBI) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Zoom Video Communications, Inc. — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while Zoom Video Communications, Inc. trades at $97.43 (market cap $27.62B). The key difference: Zoom Video Communications, Inc. is far larger — about 2.7× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Zoom Video Communications, Inc. for 92 Days on average.
| XBI | ZM | |
|---|---|---|
Market Cap | $10.11B | $27.62B |
Volume | 12,903,266 | 3,913,188 |
Sector | Broad Market / Factor | Technology |
52-Week High | $169.55 | $111.88 |
52-Week Low | $104.99 | $72.72 |
Typical Hold Time | 38 Days | 92 Days |
Enterprise Value | — | $20.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Zoom Communications (ZM) trades at $97.74, up 3.13% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a net income margin of 65.19% and ROE of 32.14%, though recent earnings were mixed with one miss and two beats. Revenue growth is steady, projected to reach $5.0B in 2026, and the company is actively investing in AI-driven revenue tools, as highlighted by recent product launches.
The outlook for ZM is positive, with a consensus price target of $118.08 offering ~21% upside, supported by analyst buy ratings. Key risks include reliance on international sales and competitive pressures in the communication software space. Cash flow trends show variability, with net cash flow negative in 2025 and 2026, requiring monitoring of capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
